# A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer

> **NCT05846594** · NA · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 463 (actual)

## Conditions studied

- Metastatic Lung Cancer
- Metastatic Gastrointestinal Cancer

## Interventions

- **DIAGNOSTIC_TEST:** FoundationOne® Liquid CDx Assay
- **DIAGNOSTIC_TEST:** Standard of Care Diagnostic Pathway

## Key facts

- **NCT ID:** NCT05846594
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-14
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 463 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846594, "A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05846594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*